Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Operating Expenses (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Operating Expenses for 5 consecutive years, with $15.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 29.68% to $15.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.1 million through Dec 2025, down 34.76% year-over-year, with the annual reading at $59.1 million for FY2025, 34.76% down from the prior year.
  • Operating Expenses hit $15.2 million in Q4 2025 for Kezar Life Sciences, up from $11.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $34.6 million in Q4 2023 to a low of $11.7 million in Q3 2025.
  • Historically, Operating Expenses has averaged $19.7 million across 5 years, with a median of $18.3 million in 2022.
  • Biggest five-year swings in Operating Expenses: surged 72.65% in 2023 and later plummeted 46.62% in 2025.
  • Year by year, Operating Expenses stood at $14.1 million in 2021, then skyrocketed by 42.05% to $20.0 million in 2022, then soared by 72.65% to $34.6 million in 2023, then crashed by 37.66% to $21.6 million in 2024, then fell by 29.68% to $15.2 million in 2025.
  • Business Quant data shows Operating Expenses for KZR at $15.2 million in Q4 2025, $11.7 million in Q3 2025, and $14.6 million in Q2 2025.